Medical cannabis developer MGC Pharmaceuticals
(ASX:MXC) has secured a Manufacturing License for its European GMP cannabis production facility.
The Company can immediately start production under this licence for pharmaceutical grade products.
The first product to be released for patients from this pipeline is CannEpil™, a phytocannabinoid-based medication for the treatment of refractory epilepsy, which will soon be available in Australia.
These will be distributed into the global market and target the increasing demand for such products.
Shares in MGC Pharmaceuticals
(ASX:MXC) up 7.94 per cent to 7c.
